Oppenheimer & Co. Inc. bought a new stake in Amedisys Inc (NASDAQ:AMED) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 1,908 shares of the health services provider’s stock, valued at approximately $232,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Alpha Quant Advisors LLC raised its position in Amedisys by 137.0% in the first quarter. Alpha Quant Advisors LLC now owns 237 shares of the health services provider’s stock worth $29,000 after purchasing an additional 137 shares in the last quarter. CWM LLC raised its position in Amedisys by 482.2% in the second quarter. CWM LLC now owns 262 shares of the health services provider’s stock worth $32,000 after purchasing an additional 217 shares in the last quarter. Tompkins Financial Corp acquired a new position in Amedisys in the second quarter worth about $37,000. Parkside Financial Bank & Trust acquired a new position in Amedisys in the second quarter worth about $80,000. Finally, NEXT Financial Group Inc acquired a new position in Amedisys in the second quarter worth about $82,000. Institutional investors and hedge funds own 89.28% of the company’s stock.

Shares of NASDAQ AMED traded up $0.66 during mid-day trading on Friday, hitting $132.31. 3,944 shares of the stock were exchanged, compared to its average volume of 199,167. The company has a market cap of $4.30 billion, a P/E ratio of 36.45, a PEG ratio of 2.00 and a beta of 1.46. The stock’s fifty day simple moving average is $132.82 and its two-hundred day simple moving average is $123.53. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.88 and a current ratio of 0.88. Amedisys Inc has a twelve month low of $97.38 and a twelve month high of $141.98.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings data on Wednesday, July 31st. The health services provider reported $1.21 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.97 by $0.24. The company had revenue of $492.98 million during the quarter, compared to analyst estimates of $489.66 million. Amedisys had a net margin of 6.84% and a return on equity of 27.23%. The company’s revenue was up 19.8% on a year-over-year basis. During the same quarter last year, the business posted $1.00 earnings per share. As a group, equities research analysts predict that Amedisys Inc will post 4.11 earnings per share for the current fiscal year.

Several research analysts recently issued reports on the stock. BidaskClub raised shares of Amedisys from a “buy” rating to a “strong-buy” rating in a research report on Friday, July 26th. ValuEngine raised shares of Amedisys from a “hold” rating to a “buy” rating in a research report on Thursday, September 5th. Oppenheimer increased their price target on shares of Amedisys from $140.00 to $150.00 in a research report on Thursday, August 1st. Barclays increased their price target on shares of Amedisys from $120.00 to $125.00 and gave the stock an “equal weight” rating in a research report on Monday, August 5th. Finally, Raymond James increased their price target on shares of Amedisys from $140.00 to $144.00 and gave the stock an “outperform” rating in a research report on Monday, July 15th. Seven analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $135.90.

In other news, COO Christopher Gerard sold 350 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $134.79, for a total transaction of $47,176.50. Following the completion of the sale, the chief operating officer now owns 25,381 shares of the company’s stock, valued at $3,421,104.99. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Michael Paul North sold 10,067 shares of the firm’s stock in a transaction that occurred on Wednesday, July 24th. The stock was sold at an average price of $130.00, for a total transaction of $1,308,710.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 22,749 shares of company stock valued at $2,986,811. Company insiders own 2.90% of the company’s stock.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.

Featured Story: What is a Leveraged Buyout (LBO)?

Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc (NASDAQ:AMED).

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.